Xencor (XNCR) Tops Q4 EPS Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Xencor (XNCR) Tops Q4 EPS Expectations

Xencor (XNCR) Doses First Patients in Phase 2 Trial of XmAb5871 for IgG4-RD and Phase 2 Trial in SLE

March 7, 2016 4:02 PM EST

Xencor, Inc. (NASDAQ: XNCR) today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).

"We are advancing XmAb5871 in IgG4-RD and SLE because of its potent, reversible B-cell inhibition and promising treatment effect demonstrated in a Phase 1b/2a study of patients with rheumatoid arthritis, as well as previous ex vivo results with XmAb5871 showing inhibition of SLE patient B-cell activation... More